A Phase 2 Study of Selinexor in People with Wilms' Tumors and Other Solid Tumors


Full Title

A Multi-Center Phase II Study of Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors


Researchers want to see how well selinexor works in people with Wilms’ tumor and other solid tumors. The people in this study are children and adults with tumors that depend on a protein called XPO1. XPO1 helps cancer cells grow by getting rid of proteins that can cause those cells to die (tumor suppressor proteins).

Selinexor keeps XPO1 from getting rid of tumor suppressor proteins. By helping to keep tumor suppressor proteins in cancer cells, selinexor may cause those cells to stop growing or die.

This study includes people with Wilms’ tumor, rhabdoid tumors, malignant peripheral nerve sheath tumors (MPNST), and other solid tumors. Their tumors came back or keep growing even after treatment. Selinexor is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You or your child must:

  • Have Wilms’ tumor, rhabdoid tumor, malignant peripheral nerve sheath tumor, or another solid tumor that depends on XPO1.
  • Have recovered from the serious side effects of previous therapies before taking selinexor.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 1 or older.


For more information or to see if you can join this study, please call 833-MSK-KIDS.




Phase II (phase 2)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID